

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) ~~Heat-sensitive~~ A heat-sensitive composition in liquid form, containing comprising

- a hydrophobic organic liquid,
- an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, and
- a bioactive substance,

which changes to the organogel form when it comes into contact with a physiological fluid, during its administration to an animal body, in particular man.

2. (Currently Amended) ~~Composition~~ The composition according to Claim 1, characterized in that wherein the organogel is formed by cooling the site of application of the said composition.

3. (Currently Amended) ~~Composition~~ The composition according to Claim 1, or 2, characterized in that it also contains further comprising a hydrophilic organic solvent capable of creating weak bonds with the organogelling substance, and that wherein the organogel forms by diffusion of the said hydrophilic organic solvent into the aqueous medium.

4. (Currently Amended) Composition The composition according to Claim 1, or 2, characterized in that the wherein said organogel has a transition temperature from the liquid state to the gel state which is lower than the temperature of the site of application ~~when the organogel is administered without a hydrophilic organic solvent~~, and a transition temperature from the gel state to the liquid state that is higher than the body temperature.

5. (Currently Amended) Composition The composition according to Claim 4, characterized in that the wherein said organogel has a transition temperature from the liquid state to the gel state of less than 30°C and a transition temperature from the gel state to the liquid state of greater than +35°C.

6. (Currently Amended) Composition The composition according to ~~one of~~ ~~Claims 3 to 5~~ Claim 3, characterized in that wherein the proportion of the hydrophilic organic solvent is less than 60% ~~and preferably less than 20%~~ by weight of the said composition.

7. (Currently Amended) Composition The composition according to ~~one of~~ ~~Claims 3 to 6~~, characterized in that the Claim 3, wherein said hydrophilic organic solvent ~~belongs to~~ is selected from the group comprising consisting of ethanol, glycerol, benzyl alcohol, propylene glycol, N-methylpyrrolidone, and dimethyl sulphoxide (DMSO), poly(ethylene) glycol of low molecular weight, chlorobutanol, furfural, N,N-dimethylacetamide, glycerol formal, isopropylideneglycerol, ethyl lactate, acetic acid and lactic acid.

8. (Currently Amended) ~~Composition~~ The composition according to Claim 7, characterized in that the wherein said hydrophilic organic solvent is ethanol.

9. (Currently Amended) ~~Composition~~ The composition according to ~~one of the preceding claims, characterized in that the~~ Claim 1, wherein said hydrophobic organic liquid ~~belongs to~~ is selected from the group ~~comprising~~ consisting of plant oils, triglycerides, semi-synthetic oils and water-immiscible organic solvents.

10. (Currently Amended) ~~Composition~~ The composition according to Claim 9, characterized in that the wherein said hydrophobic organic liquid ~~comprises~~ is selected from the group consisting of soybean oil, squalene, benzyl benzoate, a triglyceride or a mixture of benzyl benzoate and benzyl alcohol.

11. (Currently Amended) ~~Composition~~ The composition according to Claim 9, or 10, characterized in that the wherein said hydrophobic organic liquid is a mixture of different hydrophobic organic solvents.

12. (Currently Amended) ~~Composition~~ The composition according to Claim 11, characterized in that the wherein said mixture hydrophobic organic liquid is a mixture of soybean oil and ethyl oleate.

13. (Currently Amended) ~~Composition~~ The composition according to ~~one of the preceding claims, characterized in that the~~ Claim 1, wherein said biologically active

substance ~~belongs to~~ is selected from the group comprising ~~consisting of~~ proteins, peptides, amino acids, vitamins, nucleic acids and oligonucleotides.

14. (Currently Amended) ~~Composition~~ The composition according to Claim 13, characterized in that ~~the~~ wherein said biologically active substance is chosen selected from the group consisting of morphine, α -interferon, β -interferon, somatostatin, heparin, interleukins, erythropoietin, calcitonin, human growth hormone, thyrotrope hormone and leuprolide.

15. (Currently Amended) ~~Composition~~ The composition according to ~~one of the preceding claims, characterized in that~~ Claim 1, wherein the organogelling substance represents between 0.5% and 50% by weight relative to the total weight of ~~the~~ said composition.

16. (Currently Amended) ~~Composition~~ The composition according to ~~one of the preceding claims, characterized in that~~ Claim 1, wherein the organogelling substance is a molecule of low molecular weight with acid, alcohol or amine end groups[[.]] especially an amino acid derivative.

17.-19. (Canceled)

20. (Currently Amended) ~~Organogel obtained~~ An organogel formed from the composition according to ~~one of~~ Claims 1 to 18, characterized in that it remains in ~~stable~~ Claim 1, which is capable of remaining stable in gelled form between the

temperature of application and the gel/liquid transition temperature of the said composition.

21. (Currently Amended) ~~Use of a composition according to one of Claims 1 to 20, for the manufacture of a medicinal product intended to be injected~~ A method for administering a bioactive substance to an animal comprising injecting the composition according to Claim 1 into the body of said animal via the extravascular parenteral route and especially subcutaneously, intradermally, intraperitoneally or intramuscularly, or intended to be administered intraocularly or vaginally, the intraocular route or the vaginal route, to an open wound or during surgery.

22. (Canceled)

21. 23. (Currently Amended) Process A process for preparing a composition according to Claim 1, ~~characterized in that~~ wherein the bioactive substance, optionally in aqueous solution, is added to ~~the~~ a mixture consisting of comprising the organogelling substance and the hydrophobic organic liquid.

22. 24. (Currently Amended) Process A process for preparing a composition according to Claim 3, ~~which consists in~~ comprising the steps of:

- dissolving the organogelling substance in the hydrophilic organic solvent, and then in
- incorporating the bioactive substance and the hydrophobic organic liquid.

23. 25. (Currently Amended) Process A process according to Claim 22,
~~characterized in that when the bioactive substance is sparingly soluble or insoluble in~~
~~the organic phase, Claim 24, wherein~~ an aqueous solution of the said bioactive
substance is dispersed with stirring into the organic phase ~~consisting of comprising~~
the organogelling substance and the hydrophilic organic solvent, when the bioactive
substance is sparingly soluble or insoluble in the organic phase.

26. (New) The composition according to Claim 6, wherein the proportion of the hydrophilic organic solvent is less than 20% by weight of said composition.

27. (New) The composition according to Claim 10, wherein said hydrophobic organic liquid is a mixture of different hydrophobic organic solvents.

28. (New) The composition according to Claim 16, wherein the organogelling substance is an amino acid derivative.

29. (New) The composition according to Claim 28, wherein the organogelling substance is an alanine ester derivative.

30. (New) The composition according to Claim 29, wherein said organogelling substance is N-lauroyl-L-alanine methyl ester or N-lauroyl-L-alanine ethyl ester.

31. (New) The composition according to Claim 29, wherein said organogelling substance is N-stearoyl-L-alanine methyl ester or N-stearoyl-L-alanine ethyl ester.

32. (New) The method according to Claim 21, wherein said composition is injected into said body via the subcutaneous route, the intradermal route, the intraperitoneal route or the intramuscular route.

33. (New) A method for delivering a bioactive substance into an animal body for the sustained release of said bioactive substance therefrom, comprising administering said bioactive substance into said body in the form of a composition according to Claim 1.

34. (New) The method according to Claim 21, wherein the animal is a human.

35. (New) The method according to Claim 33, wherein the animal body is a human body.